Plain-English translation of NCT06898515 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medical device called the Reprieve System designed to help remove excess fluid from people hospitalized with acute decompensated heart failure. The device delivers personalized combinations of diuretics (water pills) and saline infusions to help your body get rid of fluid more efficiently. Researchers want to see if this new approach works better than standard diuretic therapy guided by current medical guidelines.
Many heart failure patients don't respond well to standard diuretics alone, making it difficult to safely remove the excess fluid that causes their symptoms. This trial exists to find out whether this new treatment approach can help those patients who are resistant to typical therapy.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new Reprieve System device or standard diuretic therapy. With the Reprieve System, you will receive personalized infusions of water pills and saline through an IV while your kidney function is monitored. With standard therapy, your diuretics will be adjusted according to established medical guidelines. You will be monitored throughout your hospital stay to track how well the treatment removes excess fluid and improves your symptoms.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States